Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Dengue

Dengue

Part of Flavivirus Infections

15 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Dengue

35 trials tracked for Dengue: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 1088 citations.

35Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 6 Phase 2 19 Phase 1 4 Other / NA 6
  1. Phase 3 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Completed · 1,088 cited
  2. Phase 3 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults Completed · 28 cited
  3. Phase 3 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Completed · 21 cited
  4. Phase 3 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed
  5. Phase 3 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed
  6. Phase 3 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed
Show 29 more trials
  1. Phase 2 A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults Completed
  2. Phase 2 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed
  3. Phase 2 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed
  4. Phase 2 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed
  5. Phase 2 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed
  6. Phase 2 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed
  7. Phase 2 A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children Completed
  8. Phase 2 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed
  9. Phase 2 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Completed
  10. Phase 2 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed
  11. Phase 2 An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge Completed
  12. Phase 2 Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) Completed
  13. Phase 2 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed
  14. Phase 2 Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) Completed
  15. Phase 2 A Phase II Trial of a Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy Adults in Thailand Completed
  16. Phase 2 Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults Completed
  17. Phase 2 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed
  18. Phase 2 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed
  19. Phase 2 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed
  20. Phase 1 Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers Completed
  21. Phase 1 ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) Completed
  22. Phase 1 Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine Completed
  23. Phase 1 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4) Completed
  24. N/A Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children Completed
  25. N/A A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components Completed
  26. N/A Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Completed
  27. N/A Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study Completed
  28. N/A Defining Skin Immunity of a Bite of Key Insect Vectors in Humans Completed
  29. N/A A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Dengue: what the trials found

Several large phase 3 trials have established the immunogenicity and safety of the CYD tetravalent dengue vaccine (live, attenuated, dengue serotypes 1-4). In a pivotal trial (N=20,869), the vaccine reduced symptomatic virologically confirmed dengue (VCD) cases compared to placebo (273 vs. 380 cases) 2. Another large trial (N=10,275) similarly showed fewer VCD cases after dose 1 (276 vs. 302) and dose 2 (205 vs. 238) 7. Seropositivity rates against all four serotypes were high post-vaccination, with antibody titers ≥10 1/dilution achieved in 72.8-94.9% of participants across serotypes 2 and 52.0-94.0% in another study 7.

Safety data from phase 3 trials indicate that the CYD vaccine is generally well tolerated. In a study of 400 participants, solicited local adverse events occurred in 34.3-56.2% and systemic events in 58.6-66.6% after vaccination, with most being mild to moderate 4. Unsolicited adverse events were reported in 25.0-30.0% 4. A phase 2 trial (N=1,198) reported solicited injection-site and systemic reactions in 53.9% and 66.7% of participants, respectively, with low rates of severe reactions (1.0-2.0%) 14. Another phase 2 study (N=4,002) found solicited injection-site reactions in 57.7% and systemic reactions in 32.2% 15. Concomitant administration with yellow fever vaccine did not impair immune responses, with seroconversion rates of 98.7-100% 6.

Immunogenicity data from phase 2 trials support robust antibody responses. A study of the tetravalent CYD vaccine (N=90) demonstrated seropositivity against all serotypes 12. Another trial (N=86) using a live attenuated tetravalent vaccine reported low rates of grade 3 solicited symptoms (0-2 subjects) and unsolicited adverse events (6 subjects) 19. A phase 2 study of a tetravalent live attenuated vaccine (N=51) showed seronegative neutralizing antibody titers after dose 2 ranging from 25.0% to 100% across serotypes 22.

Recent results — preliminary, needs further review

  • A phase 1 trial (N=29) of a new vaccine showed significant increases in dengue IgG levels post-vaccination (p<0.01) 1.
  • A phase 2 trial (N=1,364) of V181 demonstrated high neutralizing antibody titers (608.55-773.96 for serotypes 1-3) and seroconversion rates (98.6-99.2%) with no vaccine-related serious adverse events 8.
  • Another phase 2 trial (N=1,271) of V181 high-potency level reported no vaccine-related serious adverse events and solicited injection-site (15.0-35.5%) and systemic (33.9-52.8%) adverse events 9.
  • A phase 2 trial (N=192) of TV005 vaccine showed high seropositivity rates (83-99%) post-vaccination, with significant differences between dengue-experienced and naive participants (p<0.001) 11.

For the clinician treating this condition

  • CYD tetravalent dengue vaccine reduces symptomatic VCD cases and induces seropositivity against all four serotypes in a majority of recipients.
  • The vaccine has an acceptable safety profile, with mostly mild-to-moderate solicited local and systemic reactions.
  • Recent trials of V181 and TV005 vaccines show promising immunogenicity and safety, but data are not yet established.

AI synthesis of 13 cited trials, updated Jun 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Field report examines dengue virus infection prevalence in U.S. Virgin Islands youth
Pediatrics
Field report examines dengue virus infection prevalence in U.S. Virgin Islands youth How many kids in the U.S. Virgin Islands have had dengue?
A field report from the U.S. Virgin Islands assessed the prevalence of previous dengue virus infection in children and adolescents.
Health officials in the U.S. Virgin Islands are checking how common past dengue infections are among children and adolescents.
CDC Apr 4, 2026
Review suggests T cell epitope vaccines may help control dengue infection and modulate ADE risk
Allergy & Immunology Sys. Review
Review suggests T cell epitope vaccines may help control dengue infection and modulate ADE risk Could targeting T cells lead to a safer dengue vaccine?
A systematic review examines research on dengue virus T cell epitope-mediated immunity and antibody-dependent enhancement (ADE).
A new dengue vaccine strategy targeting T cells could help control the virus and reduce the risk of severe disease from antibody-dependent e…
Frontiers Apr 2, 2026
Release of Wolbachia-infected male mosquitoes reduced dengue risk by 71-72% in Singapore trial
Pediatrics RCT
Release of Wolbachia-infected male mosquitoes reduced dengue risk by 71-72% in Singapore trial Can releasing special male mosquitoes stop dengue? A trial in Singapore shows promising results
In a cluster-randomized trial in Singapore, releasing male Aedes aegypti mosquitoes infected with the AlbB strain of Wolbachia bacteria supp…
Releasing male mosquitoes infected with harmless bacteria in Singapore sharply cut dengue cases, dropping infection odds by 71% to 72% for r…
Mar 30, 2026

Questions about Dengue

Can T cell epitope vaccines help control dengue virus infection?

T cell epitope vaccines show promise for controlling dengue by boosting cellular immunity and potentially reducing the risk of severe disease caused by antibody-dependent enhancement.

Full answer →
Why did travel-associated Dengue cases increase in the United States in 2019?

Travel-associated dengue cases in the U.S. surged in 2019 due to high global dengue activity and increased travel to endemic areas, with 1,474 cases reported — 168% above the annual average for other years.

Full answer →
What are the current epidemiologic trends of Dengue in U.S. Territories?

Dengue cases in U.S. Territories have risen significantly, with Puerto Rico declaring a local public health emergency in 2024 due to a surge in infections.

Full answer →
Why did Dengue cases increase in Peru during the year 2023?

Dengue cases rose in Peru in 2023 due to a combination of climate-driven environmental changes and the circulation of specific virus serotypes that increase severe disease risk.

Full answer →
Can clinical prediction models help identify Dengue cases in Brazil?

Yes, clinical prediction models using symptoms like leukopenia and vomiting can help identify dengue cases in Brazil, with good accuracy in a recent study.

Full answer →
See all 5 questions about Dengue →